8-K current report · filed Oct 9, 2026

MYRIAD GENETICS INC (MYGN) 8-K Current Report: October 9, 2026

Item 5.02MYGN overview

Short answer

MYRIAD GENETICS INC (MYGN) filed an 8-K current report with the SEC on October 9, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Former Chief Commercial Officer Brian Donnelly’s separation became effective September 21, 2026.

MYRIAD GENETICS INC 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Former Chief Commercial Officer Brian Donnelly’s separation became effective September 21, 2026
  • $1,322,294 lump-sum severance payment, subject to release and restrictive covenants
  • Time-based equity awards vesting within two years accelerated, increasing near-term compensation expense
  • Performance-based awards remain contingent on achievement through two years after separation
  • Agreement effective October 14, 2026, unless Donnelly revokes it

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other MYRIAD GENETICS INC 8-K filings

Get the next MYGN 8-K as it lands

Follow MYGN for push alerts, or ask the research agent what this filing means.